Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Mar
17
Today In Oncology
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New Prostate Cancer Risk Classification With PSMA-PET
FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo